Palliative thoracic radiotherapy in lung cancer: An American Society for Radiation Oncology evidence-based clinical practice guideline

Practical Radiation Oncology

Volumn 1, Issue 2, 2011, Pages 60-71

  Rodrigues, George ^a   Videtic, Gregory M M ^b   Sur, Ranjan ^c   Bezjak, Andrea ^d   Bradley, Jeffrey ^e   Hahn, Carol A ^f   Langer, Corey ^g   Miller, Keith L ^h   Moeller, Benjamin J ⁱ   Rosenzweig, Kenneth ^j   Movsas, Benjamin ^k  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h 21ST CENTURY ONCOLOGY   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k HENRY FORD HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; NAVELBINE; PEMETREXED;

ARTICLE; BRACHYTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DOSE RESPONSE; DRUG DOSE ESCALATION; ESOPHAGITIS; EVIDENCE BASED PRACTICE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIATION RESPONSE; SKIN MANIFESTATION; SPINAL CORD DISEASE; STOMATITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION;

EID: 84857944393     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2011.01.005     Document Type: Article

References (56)

1. Scottish Intercollegiate Guidelines Network Management of patients with lung cancer: a national clinical guideline Available at:, Accessed July 13, 2010. http://www.sign.ac.uk/pdf/sign80.pdf.
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997, 15:2996-3018.
3. Graham M.V., Byhardt R.W., Sause W.T., et al. Non-aggressive, non-surgical treatment of inoperable non-small cell lung cancer (NSCLC). American College of Radiology. ACR Appropriateness Criteria. Radiology 2000, 215(suppl):1347-1362.
4. Lester J.F., Macbeth F.R., Toy E., et al. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2006, 4:CD002143.
5. National Comprehensive Cancer Network Treatment guidelines-NCCN clinical practice guidelines in oncology non-small cell lung cancer V.2, 2010 Available at:, Accessed July 13, 2010. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
6. Okawara G, Mackay JA, Evans WK, et al. Lung Cancer Disease Site Group of Cancer Care Ontario's program in evidence-based care. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 2006, 1:377-393.
7. Ung Y.C., Yu E., Falkson C., et al. The role of high-dose-rate brachytherapyin the palliation of symptoms in patients with non-small cell lung cancer: a systematic review. Brachytherapy 2006, 5:189-202.
8. Cardona A.F., Reveiz L., Ospina E.G., et al. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2008, 2:CD004284.
9. Macbeth F.R., Abratt R.P., Cho K.H., et al. International Atomic Energy Agency. Lung cancer management in limited resource settings: guidelines for appropriate good care. Radiother Oncol 2007, 82:123-131.
10. Tang J.I., Shakespeare T.P., Lu J.J., et al. Patients' preference for radiotherapy fractionation schedule in the palliation of symptomatic unresectable lung cancer. J Med Imaging Radiat Oncol 2008, 52:497-502.
11. van den Hout W.B., Kramer G.W., Noordijk E.M., Leer J.W. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small cell lung cancer. J Natl Cancer Inst 2006, 98:1786-1794.
12. Timothy A.R., Girling D.J., Saunders M.I., et al. Second Workshop on Palliative Radiotherapy and Symptom Control. Radiotherapy for inoperable lung cancer. Clin Oncol (R Coll Radiol) 2001, 13:86-87.
13. Physician Consortium for Performance Improvement The evidence base required for measure development Available at:, Accessed July 12, 2010. http://www.ama-assn.org/ama/pub/physician-resources/clinical-practice-improvement/clinical-quality/physician-consortium-performance-improvement/position-papers.shtml.
14. Sniderman A.D., Furberg C.D. Why guideline-making requires reform. JAMA 2009, 301:429-431.
15. Simpson J.R., Francis M.E., Perez-Tamayo R., et al. Palliative radiotherapy for inoperable carcinoma of the lung: final report of an RTOG multi-institutional trial. Int J Radiat Oncol Biol Phys 1985, 11:751-758.
16. Teo P., Tai T.H., Choy D., et al. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1988, 14:867-871.
17. Medical Research Council Lung Cancer Working Party Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 1991, 63:265-270.
18. Medical Research Council Lung Cancer Working Party A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small cell lung cancer (NSCLC) and poor performance status. Br J Cancer 1992, 65:934-941.
19. Abratt R.P., Shepherd L.J., Mameena Salton D.G. Palliative radiation for stage 3 non-small cell lung cancer-a prospective study of two moderately high dose regimens. Lung Cancer 1995, 13:137-143.
20. Medical Research Council Lung Cancer Working Party Randomized trial of palliative two-fraction versus more intensive thirteen fraction radiotherapy for patients with inoperable nonsmall cell lung cancer and good performance status. Clin Oncol 1996, 8:167-175.
21. Rees G.J., Devrell C.E., Barley V.L., et al. Palliative radiotherapy for lung cancer; two versus five fractions. Clin Oncol 1997, 9:90-95.
22. Reinfuss M., Glinski B., Kowalska T., et al. Radiotherapy in stage III, unresectable, asymptomatic non-small cell lung cancer. Final results of a prospective randomized study of 240 patients. Cancer Radiother 1999, 3:475-479.
23. Nestle U., Nieder N., Walter K., et al. A palliative accelerated irradiation regimen for advanced non-small cell lung cancer vs conventionally fractionated 60 Gy: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys 2000, 48:95-103.
24. Bezjak A., Dixon P., Brundage M., et al. Randomized phase III trial of single versus fractionated thoracic radation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 2002, 54:719-728.
25. Sundstrom S., Bremnes R., Aasebo U., et al. Hypofractionated palliative radiotherapy (17Gy per 2 fractions) in advanced non-small cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol 2004, 22:801-810.
26. Erridge S.C., Gaze M.N., Price A., et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol 2005, 17:61-67.
27. Kramer G.W., Wanders S.L., Noordijk E.M., et al. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small cell lung cancer. J Clin Oncol 2005, 23:2962-2970.
28. Senkus-Konefka E., Dziadziuszko R., Bednaruk-Mlynski E., et al. A prospective randomised study to compare two palliative radiotherapy schedules for non-small cell lung cancer (NSCLC). Br J Cancer 2005, 92:1038-1045.
29. Lester J.F., Macbeth F.R., Toy E., et al. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2009, 1:1.
30. Fairchild A., Harris K., Barnes E., et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008, 26:4001-4011.
31. Kepka L., Olszyna-Serementa M. Palliative thoracic radiotherapy for lung cancer. Expert Rev Anticancer Ther 2010, 10:559-569.
32. Macbeth F., Stephens R. Palliative treatment for advanced non-small cell lung cancer. Hematol Oncol Clin North Am 2004, 18:115-130.
33. Mallick I., Sharma S.C., Behera D., et al. Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in palliative management of non-small cell lung cancer: a prospective randomized study. J Can Res Ther 2006, 2:119-125.
34. Sur R., Ahmed S.N., Donde B., et al. Brachytherapy boost vs teletherapy boost in palliation of symptomatic, locally advanced non-small cell lung cancer: preliminary analysis of a randomized, prospective study. J Brachyther Int 2001, 17:309-315.
35. Sur R., Donde B., Mohuiddin M., et al. Randomized prospective study on the role of high dose rate intraluminal brachytherapy (HDRILBT) in palliation of symptoms in advanced non-small cell lung cancer (NSCLC) treated with radiation alone [abstract]. Int J Radiat Oncol Biol Phys 2004, 60:S205.
36. Langendijk H., de Jong J., Tjwa M., et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol 2001, 58:257-268.
37. Chella A., Ambrogi M.C., Ribechini A., et al. Combined Nd-YAG laser/HDR brachytherapy versus Nd-YAG laser only in malignant central airway involvement: a prospective randomized study. Lung Cancer 2000, 27:169-175.
38. Stout R., Barber P., Burt P., et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol 2000, 56:323-327.
39. Huber R.M., Fischer R., Hautmann H., et al. Palliative endobronchial brachytherapy for central lung tumors. A prospective, randomized comparison of two fractionation schedules. Chest 1995, 107:463-470.
40. Mantz C.A., Dosoretz D.E., Rubenstein J.H., et al. Endobronchial brachytherapy and optimization of local disease control in medically inoperable non-small cell lung carcinoma: a matched-pair analysis. Brachytherapy 2004, 3:183-190.
41. Huber R.M., Fischer R., Hautmann H., et al. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 1997, 38:533-540.
42. Ball D., Smith J., Bishop J., et al. A phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small cell lung cancer. Br J Cancer 1997, 75:690-697.
43. Anderson H., Hopwood P., Stephens R.J., et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. Br J Cancer 2001, 85:137-138.
44. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
45. Curran W., Scott C., Langer C., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 94-10 [abstract]. Proc Am Soc Clin Oncol 2003, 22:2499.
46. Michael M., Wirth A., Ball D.L., et al. A phase I trial of high-dose palliative radiotherapy plus concurrent weekly vinorelbine and cisplatin in patients with locally advanced and metastatic NSCLC. Br J Cancer 2005, 93:652-661.
47. Hoffman P.C., Cohen E.E., Masters G.A., et al. Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer. Lung Cancer 2002, 38:65-71.
48. Seiwert T.Y., Connell P.P., Mauer A.M., et al. A phase I study of pemetrexed carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007, 13:515-522.
49. Reinfuss M., Glinski B., Kowalska T., et al. Radiotherapy for stage III, inoperable asymptomatic non-small cell lung cancer. Final results of a prospective randomized study (240 patients). Cancer Radiother 1999, 3:475-479.
50. Jeremic B., Shibamoto Y., Milicic B., et al. Short-term chemotherapy and palliative radiotherapy for elderly patients with stage IV non-small cell lung cancer-a phase II study. Lung Cancer 1999, 24:1-9.
51. Schwarzenberger P., Theodossiou C., Barron S., et al. Dose escalation of docetaxel concomitant with hypofractionated, once weekly chest radiotherapy for non-small cell lung cancer-a phase I study. Am J Clin Oncol 2004, 27:395-399.
52. Choi B., Robins H.I., Schiller J., et al. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer. Cancer Chemother Pharmacol 2008, 63:175-179.
53. Silvano G., Campoccia S., Colosimo S., et al. Vinorelbine and hypofractionated radiotherapy as a palliative treatment in patients affected by non small cell lung cancer: a phase I study [abstract]. Proc Am Soc Clin Oncol 2000, 19:2048.
54. Spigel D.R., Hainsworth J.D., Yardley D.A., et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010, 28:43-48.
55. Hirsh V., Soulieres D., Duclos M., et al. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol 2007, 2:927-932.
56. Ready N., Jänne P.A., Bogart J., et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALGB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010, 5:1382-1390.